← Eichor
Study identifier: NCT07699614 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Lung Health and the Microbiome Among Adults in Botswana: the Go-hema Cohort

Condition: Obstructive Pulmonary Disease · Restrictive Pulmonary Disease  ·  Sponsor: Duke University

PhaseN/A
Planned participants900
Who can joinAll sexes, 35 Years to no upper limit
Healthy volunteersYes

About this study

Chronic respiratory diseases like chronic obstructive pulmonary disease (COPD) are responsible for millions of deaths each year, the majority of which occur in low- and middle-income countries (LMICs). LMICs also have high rates of abnormal lung function, including restrictive spirometric pattern (RSP), which can precede the development of chronic respiratory diseases and is associated with all-cause mortality. Additionally, LMICs in sub-Saharan Africa are home to the majority of the world's population of people with HIV (PWH). HIV increases the risk of COPD and COPD associated mortality, but the mechanisms underlying this risk are incompletely understood.

This description comes directly from the study's public registry record.

Talk to the study team

Relebogile Thipe, Nursing  ·  +2673170933  ·  thre2001@gmail.com

Sweta Patel, Medical  ·  : (919) 668-0325  ·  sweta.patel@duke.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Local Health Facilities in GaboroneGaborone, BotswanaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07699614